{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,19]],"date-time":"2026-07-19T10:57:15Z","timestamp":1784458635668,"version":"3.55.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,11,12]],"date-time":"2019-11-12T00:00:00Z","timestamp":1573516800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,11,12]],"date-time":"2019-11-12T00:00:00Z","timestamp":1573516800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1007\/s00415-019-09622-4","type":"journal-article","created":{"date-parts":[[2019,11,12]],"date-time":"2019-11-12T18:03:05Z","timestamp":1573581785000},"page":"674-678","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Intravenous cyclophosphamide monthly pulses in refractory myasthenia gravis"],"prefix":"10.1007","volume":"267","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0206-322X","authenticated-orcid":false,"given":"Enrique","family":"Gomez-Figueroa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sof\u00eda","family":"Garcia-Trejo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisette","family":"Bazan-Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Cervantes-Uribe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"German","family":"Chac-Lezama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Carlos","family":"L\u00f3pez-Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Vargas-Ca\u00f1as","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,11,12]]},"reference":[{"key":"9622_CR1","doi-asserted-by":"publisher","DOI":"10.1111\/cei.12217","author":"JP Sieb","year":"2014","unstructured":"Sieb JP (2014) Myasthenia gravis: an update for the clinician. Clin Exp Immunol. https:\/\/doi.org\/10.1111\/cei.12217","journal-title":"Clin Exp Immunol"},{"key":"9622_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/nri916","author":"A Vincent","year":"2002","unstructured":"Vincent A (2002) Unravelling the pathogenesis of myasthenia gravis. Nat Rev Immunol. https:\/\/doi.org\/10.1038\/nri916","journal-title":"Nat Rev Immunol"},{"key":"9622_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2014.11.022","author":"JC Ha","year":"2015","unstructured":"Ha JC, Richman DP (2015) Myasthenia gravis and related disorders: Pathology and molecular pathogenesis. Biochim Biophys Acta-Mol Basis Dis. https:\/\/doi.org\/10.1016\/j.bbadis.2014.11.022","journal-title":"Biochim Biophys Acta-Mol Basis Dis"},{"key":"9622_CR4","doi-asserted-by":"publisher","DOI":"10.1002\/mus.20030","author":"JC Keesey","year":"2004","unstructured":"Keesey JC (2004) Clinical evaluation and management of myasthenia gravis. Muscle Nerve. https:\/\/doi.org\/10.1002\/mus.20030","journal-title":"Muscle Nerve"},{"key":"9622_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(15)00145-3","author":"NE Gilhus","year":"2015","unstructured":"Gilhus NE, Verschuuren JJ (2015) Myasthenia gravis: Subgroup classification and therapeutic strategies. Lancet Neurol. https:\/\/doi.org\/10.1016\/S1474-4422(15)00145-3","journal-title":"Lancet Neurol"},{"key":"9622_CR6","doi-asserted-by":"publisher","first-page":"175628561774913","DOI":"10.1177\/1756285617749134","volume":"11","author":"R Mantegazza","year":"2018","unstructured":"Mantegazza R, Antozzi C (2018) When myasthenia gravis is deemed refractory: clinical signposts and treatment strategies. Ther Adv Neurol Disord 11:1756285617749134\u20131756285617749134. https:\/\/doi.org\/10.1177\/1756285617749134","journal-title":"Ther Adv Neurol Disord"},{"issue":"4","key":"9622_CR7","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","volume":"87","author":"DB Sanders","year":"2016","unstructured":"Sanders DB, Wolfe GI, Benatar M et al (2016) International consensus guidance for management of myasthenia gravis. Neurology. 87(4):419\u2013425. https:\/\/doi.org\/10.1212\/WNL.0000000000002790","journal-title":"Neurology."},{"key":"9622_CR8","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e318207b1f6","author":"I Cortese","year":"2011","unstructured":"Cortese I, Chaudhry V, So YT, Cantor F, Cornblath DR, Rae-Grant A (2011) Evidence-based guideline update: plasmapheresis in neurologic disorders: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. https:\/\/doi.org\/10.1212\/WNL.0b013e318207b1f6","journal-title":"Neurology"},{"key":"9622_CR9","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000256698.69121.45","author":"L Zinman","year":"2007","unstructured":"Zinman L, Ng E, Bril V (2007) IV immunoglobulin in patients with myasthenia gravis: a randomized controlled trial. Neurology. https:\/\/doi.org\/10.1212\/01.wnl.0000256698.69121.45","journal-title":"Neurology"},{"key":"9622_CR10","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002277.pub3","author":"P Gajdos","year":"2008","unstructured":"Gajdos P, Chevret S, Toyka K (2008) Intravenous immunoglobulin for myasthenia gravis. Cochrane Database Syst Rev. https:\/\/doi.org\/10.1002\/14651858.CD002277.pub3","journal-title":"Cochrane Database Syst Rev"},{"key":"9622_CR11","doi-asserted-by":"publisher","DOI":"10.1046\/j.1526-0968.2000.004004275.x","author":"AP Batocchi","year":"2000","unstructured":"Batocchi AP, Evoli A, Di SC, Tonali P (2000) Therapeutic apheresis in myasthenia gravis. Ther Apher. https:\/\/doi.org\/10.1046\/j.1526-0968.2000.004004275.x","journal-title":"Ther Apher"},{"key":"9622_CR12","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2003.019232","author":"DE Gladstone","year":"2004","unstructured":"Gladstone DE, Brannagan TH, Schwartzman RJ, Prestrud AA, Brodsky I (2004) High dose cyclophosphamide for severe refractory myasthenia gravis. J Neurol Neurosurg Psychiatry. https:\/\/doi.org\/10.1136\/jnnp.2003.019232","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"9622_CR13","doi-asserted-by":"publisher","DOI":"10.1002\/mus.20411","author":"PT Lin","year":"2006","unstructured":"Lin PT, Martin BA, Weinacker AB, So YT (2006) High-dose cyclophosphamide in refractory myasthenia gravis with MuSK antibodies. Muscle Nerve. https:\/\/doi.org\/10.1002\/mus.20411","journal-title":"Muscle Nerve"},{"key":"9622_CR14","doi-asserted-by":"publisher","DOI":"10.3109\/08916930903518107","author":"DB Sanders","year":"2010","unstructured":"Sanders DB, Evoli A (2010) Immunosuppressive therapies in myasthenia gravis. Autoimmunity. https:\/\/doi.org\/10.3109\/08916930903518107","journal-title":"Autoimmunity"},{"key":"9622_CR15","doi-asserted-by":"publisher","DOI":"10.1002\/mus.21521","author":"N Zebardast","year":"2010","unstructured":"Zebardast N, Patwa HS, Novella SP, Goldstein JM (2010) Rituximab in the management of refractory myasthenia gravis. Muscle Nerve. https:\/\/doi.org\/10.1002\/mus.21521","journal-title":"Muscle Nerve"},{"key":"9622_CR16","doi-asserted-by":"publisher","DOI":"10.1002\/mus.25597","author":"R Tandan","year":"2017","unstructured":"Tandan R, Hehir MK, Waheed W, Howard DB (2017) Rituximab treatment of myasthenia gravis: a systematic review. Muscle Nerve. https:\/\/doi.org\/10.1002\/mus.25597","journal-title":"Muscle Nerve"},{"key":"9622_CR17","doi-asserted-by":"publisher","DOI":"10.1002\/mus.10133","author":"LG De Feo","year":"2002","unstructured":"De Feo LG, Schottlender J, Martelli NA, Molfino NA (2002) Use of intravenous pulsed cyclophosphamide in severe, generalized myasthenia gravis. Muscle Nerve. https:\/\/doi.org\/10.1002\/mus.10133","journal-title":"Muscle Nerve"},{"key":"9622_CR18","doi-asserted-by":"publisher","DOI":"10.1002\/ana.10400","author":"DB Drachman","year":"2003","unstructured":"Drachman DB, Jones RJ, Brodsky RA (2003) Treatment of refractory myasthenia: \u201cRebooting\u201d with high-dose cyclophosphamide. Ann Neurol. https:\/\/doi.org\/10.1002\/ana.10400","journal-title":"Ann Neurol"},{"key":"9622_CR19","doi-asserted-by":"publisher","DOI":"10.1002\/mus.24536","author":"KA Buzzard","year":"2015","unstructured":"Buzzard KA, Meyer NJ, Hardy TA, Riminton DS, Reddel SW (2015) Induction intravenous cyclophosphamide followed by maintenance oral immunosuppression in refractory myasthenia gravis. Muscle Nerve. https:\/\/doi.org\/10.1002\/mus.24536","journal-title":"Muscle Nerve"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-019-09622-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00415-019-09622-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-019-09622-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,11]],"date-time":"2020-11-11T00:09:18Z","timestamp":1605053358000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00415-019-09622-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,12]]},"references-count":19,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["9622"],"URL":"https:\/\/doi.org\/10.1007\/s00415-019-09622-4","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,12]]},"assertion":[{"value":"4 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All authors declare no competing interests or external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Authors have read the journal's position on issues involved in ethical publication. This study was approved by the research ethics committee of our institution.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}}]}}